# Kymera Therapeutics, Inc.: financial statements, quarterly

KYMR · Nasdaq · CIK 1815442 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kymr.md) · [Financials](/companies/kymr/financials.md) · [Filings](/companies/kymr/filings.md) · [Insiders](/companies/kymr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kymr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.7](/filings/0000950170-24-119249.md) | [47.9 d](/filings/0001193125-26-073395.md) | [10.3](/filings/0000950170-25-067498.md) | [25.7](/filings/0000950170-25-106229.md) | [3.7](/filings/0001193125-25-263550.md) | [7.4 d](/filings/0001193125-26-073395.md) | [22.1](/filings/0001193125-26-193967.md) | [11.5](/filings/0001193125-26-333849.md) | [2.8](/filings/0001193125-25-263550.md) | [2.9 d](/filings/0001193125-26-073395.md) | [34.4](/filings/0001193125-26-193967.md) | [65.0](/filings/0001193125-26-333849.md) |
| Cost of revenue | $m | not reported | not reported | [10.3](/filings/0000950170-25-067498.md) | [25.7](/filings/0000950170-25-106229.md) | [3.7](/filings/0001193125-25-263550.md) | [7.4 d](/filings/0001193125-26-073395.md) | [22.1](/filings/0001193125-26-193967.md) | [11.5](/filings/0001193125-26-333849.md) | [2.8](/filings/0001193125-25-263550.md) | [2.9 d](/filings/0001193125-26-073395.md) | [34.4](/filings/0001193125-26-193967.md) | [65.0](/filings/0001193125-26-333849.md) |
| Research and development | $m | [48.1](/filings/0000950170-24-119249.md) | [53.0 d](/filings/0001193125-26-073395.md) | [48.8](/filings/0000950170-25-067498.md) | [59.2](/filings/0000950170-25-106229.md) | [60.4](/filings/0001193125-25-263550.md) | [71.8 d](/filings/0001193125-26-073395.md) | [80.3](/filings/0001193125-26-193967.md) | [78.4](/filings/0001193125-26-333849.md) | [74.1](/filings/0001193125-25-263550.md) | [83.8 d](/filings/0001193125-26-073395.md) | [98.2](/filings/0001193125-26-193967.md) | [119](/filings/0001193125-26-333849.md) |
| Operating income | $m | [(57.5)](/filings/0000950170-24-119249.md) | [(19.3) d](/filings/0001193125-26-073395.md) | [(57.8)](/filings/0000950170-25-067498.md) | [(50.9)](/filings/0000950170-25-106229.md) | [(72.1)](/filings/0001193125-25-263550.md) | [(80.8) d](/filings/0001193125-26-073395.md) | [(74.4)](/filings/0001193125-26-193967.md) | [(84.6)](/filings/0001193125-26-333849.md) | [(92.5)](/filings/0001193125-25-263550.md) | [(97.9) d](/filings/0001193125-26-073395.md) | [(84.2)](/filings/0001193125-26-193967.md) | [(75.6)](/filings/0001193125-26-333849.md) |
| Income tax | $m | [0.1](/filings/0000950170-23-057743.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(52.9)](/filings/0000950170-24-119249.md) | [(14.4) d](/filings/0001193125-26-073395.md) | [(48.6)](/filings/0000950170-25-067498.md) | [(42.1)](/filings/0000950170-25-106229.md) | [(62.5)](/filings/0001193125-25-263550.md) | [(70.8) d](/filings/0001193125-26-073395.md) | [(65.6)](/filings/0001193125-26-193967.md) | [(76.6)](/filings/0001193125-26-333849.md) | [(82.2)](/filings/0001193125-25-263550.md) | [(87.0) d](/filings/0001193125-26-073395.md) | [(69.2)](/filings/0001193125-26-193967.md) | [(61.2)](/filings/0001193125-26-333849.md) |
| Diluted EPS | $ per share | [(0.90)](/filings/0000950170-24-119249.md) | not reported | [(0.69)](/filings/0000950170-25-067498.md) | [(0.58)](/filings/0000950170-25-106229.md) | [(0.82)](/filings/0001193125-25-263550.md) | not reported | [(0.82)](/filings/0001193125-26-193967.md) | [(0.95)](/filings/0001193125-26-333849.md) | [(0.94)](/filings/0001193125-25-263550.md) | not reported | [(0.71)](/filings/0001193125-26-193967.md) | [(0.62)](/filings/0001193125-26-333849.md) |
| Basic EPS | $ per share | [(0.90)](/filings/0000950170-24-119249.md) | not reported | [(0.69)](/filings/0000950170-25-067498.md) | [(0.58)](/filings/0000950170-25-106229.md) | [(0.82)](/filings/0001193125-25-263550.md) | not reported | [(0.82)](/filings/0001193125-26-193967.md) | [(0.95)](/filings/0001193125-26-333849.md) | [(0.94)](/filings/0001193125-25-263550.md) | not reported | [(0.71)](/filings/0001193125-26-193967.md) | [(0.62)](/filings/0001193125-26-333849.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [81.1](/filings/0000950170-24-119249.md) | [110](/filings/0001193125-26-073395.md) | [93.5](/filings/0000950170-25-067498.md) | [67.6](/filings/0000950170-25-106229.md) | [111](/filings/0001193125-25-263550.md) | [120](/filings/0001193125-26-073395.md) | [90.0](/filings/0001193125-26-193967.md) | [336](/filings/0001193125-26-333849.md) | [113](/filings/0001193125-25-263550.md) | [357](/filings/0001193125-26-333849.md) | [144](/filings/0001193125-26-193967.md) | [124](/filings/0001193125-26-333849.md) |
| Current assets | $m | [376](/filings/0000950170-23-057743.md) | [405](/filings/0000950170-25-028355.md) | [537](/filings/0000950170-24-051567.md) | [525](/filings/0000950170-24-092275.md) | [569](/filings/0000950170-24-119249.md) | [510](/filings/0001193125-26-073395.md) | [501](/filings/0000950170-25-067498.md) | [728](/filings/0000950170-25-106229.md) | [528](/filings/0001193125-25-263550.md) | [871](/filings/0001193125-26-333849.md) | [677](/filings/0001193125-26-193967.md) | [737](/filings/0001193125-26-333849.md) |
| Total assets | $m | [552](/filings/0000950170-23-057743.md) | [576](/filings/0000950170-25-028355.md) | [868](/filings/0000950170-24-051567.md) | [826](/filings/0000950170-24-092275.md) | [1,035](/filings/0000950170-24-119249.md) | [978](/filings/0001193125-26-073395.md) | [918](/filings/0000950170-25-067498.md) | [1,131](/filings/0000950170-25-106229.md) | [1,102](/filings/0001193125-25-263550.md) | [1,743](/filings/0001193125-26-333849.md) | [1,669](/filings/0001193125-26-193967.md) | [1,645](/filings/0001193125-26-333849.md) |
| Current liabilities | $m | [63.2](/filings/0000950170-23-057743.md) | [85.7](/filings/0000950170-25-028355.md) | [56.1](/filings/0000950170-24-051567.md) | [62.1](/filings/0000950170-24-092275.md) | [66.5](/filings/0000950170-24-119249.md) | [67.8](/filings/0001193125-26-073395.md) | [59.0](/filings/0000950170-25-067498.md) | [87.5](/filings/0000950170-25-106229.md) | [71.6](/filings/0001193125-25-263550.md) | [83.2](/filings/0001193125-26-333849.md) | [62.6](/filings/0001193125-26-193967.md) | [71.3](/filings/0001193125-26-333849.md) |
| Total liabilities | $m | [157](/filings/0000950170-23-057743.md) | [181](/filings/0000950170-25-028355.md) | [157](/filings/0000950170-24-051567.md) | [141](/filings/0000950170-24-092275.md) | [142](/filings/0000950170-24-119249.md) | [142](/filings/0001193125-26-073395.md) | [132](/filings/0000950170-25-067498.md) | [160](/filings/0000950170-25-106229.md) | [156](/filings/0001193125-25-263550.md) | [163](/filings/0001193125-26-333849.md) | [129](/filings/0001193125-26-193967.md) | [136](/filings/0001193125-26-333849.md) |
| Shareholders' equity | $m | [396](/filings/0000950170-24-119249.md) | [395](/filings/0001193125-26-073395.md) | [711](/filings/0000950170-25-106229.md) | [685](/filings/0001193125-25-263550.md) | [893](/filings/0001193125-25-263550.md) | [836](/filings/0001193125-26-333849.md) | [786](/filings/0001193125-26-333849.md) | [971](/filings/0001193125-26-333849.md) | [946](/filings/0001193125-25-263550.md) | [1,580](/filings/0001193125-26-333849.md) | [1,540](/filings/0001193125-26-333849.md) | [1,509](/filings/0001193125-26-333849.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(31.6) d](/filings/0000950170-24-119249.md) | [8.0 d](/filings/0001193125-26-073395.md) | [(39.6)](/filings/0000950170-25-067498.md) | [(42.9) d](/filings/0000950170-25-106229.md) | [(50.2) d](/filings/0001193125-25-263550.md) | [(61.8) d](/filings/0001193125-26-073395.md) | [(79.2)](/filings/0001193125-26-193967.md) | [(59.9) d](/filings/0001193125-26-333849.md) | [(27.1) d](/filings/0001193125-25-263550.md) | [(66.7) d](/filings/0001193125-26-073395.md) | [(88.8)](/filings/0001193125-26-193967.md) | [(54.1) d](/filings/0001193125-26-333849.md) |
| Capital expenditure | $m | [8.1 d](/filings/0000950170-24-119249.md) | [11.6 d](/filings/0001193125-26-073395.md) | [7.4](/filings/0000950170-25-067498.md) | [4.7 d](/filings/0000950170-25-106229.md) | [(0.2) d](/filings/0001193125-25-263550.md) | [0.9 d](/filings/0001193125-26-073395.md) | [0.5](/filings/0001193125-26-193967.md) | [0.7 d](/filings/0001193125-26-333849.md) | [0.2 d](/filings/0001193125-25-263550.md) | [0.1 d](/filings/0001193125-26-073395.md) | [0.4](/filings/0001193125-26-193967.md) | [0.5 d](/filings/0001193125-26-333849.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [54.5](/filings/0000950170-23-057743.md) | [58.2](/filings/0000950170-24-051567.md) | [58.3](/filings/0000950170-24-092275.md) | [58.4](/filings/0000950170-24-119249.md) | [70.8](/filings/0000950170-25-067498.md) | [73.1](/filings/0000950170-25-106229.md) | [76.1](/filings/0001193125-25-263550.md) | [80.1](/filings/0001193125-26-193967.md) | [80.4](/filings/0001193125-26-333849.md) | [87.3](/filings/0001193125-25-263550.md) | [97.5](/filings/0001193125-26-193967.md) | [98.2](/filings/0001193125-26-333849.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 83,150,618 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-333849.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.